You are using an out of date browser. It may not display this or other websites correctly. You should upgrade or use an alternative browser.
n781
Alteplase (t-PA) is a thrombolytic medication, used to treat acute ST elevation myocardial infarction (a type of heart attacks), pulmonary embolism associated with low blood pressure, acute ischemic stroke, and blocked central venous access devices (CVAD). It is given by injection into a vein or artery.Common side effects are bleeding including intracranial bleeding and GI bleeding. Other side effects may rarely include allergic reactions. It is not recommended in those allergic to gentamicin. Safety of use in pregnancy is unclear. Alteplase is a manufactured form of tissue plasminogen activator. It works by converting plasminogen to plasmin in a blood clot.Alteplase was approved for medical use in the United States in 1987. It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. In the United Kingdom it costs about £864 per treatment as of 2018. In the United States this amount costs about US$9,197 as of 2019.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.